Authors: Boyle, CD Chackalamannil, S Clader, JW Greenlee, WJ Josien, HB Kaminski, JJ Kozlowski, JA McCombie, SW Nazareno, DV Tagat, JR Wang, YG Zhou, GW Billard, W Binch, H Crosby, G Cohen-Williams, M Coffin, VL Cox, KA Grotz, DE Duffy, RA Ruperto, V Lachowicz, JE

Citation: Cd. Boyle et al., Metabolic stabilization of benzylidene ketal M-2 muscarinic receptor antagonists via halonaphthoic acid substitution, BIOORG MED, 11(17), 2001, pp. 2311-2314

Authors: Tagat, JR McCombie, SW Steensma, RW Lin, SI Nazareno, DV Baroudy, B Vantuno, N Xu, S Liu, J

Citation: Jr. Tagat et al., Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element, BIOORG MED, 11(16), 2001, pp. 2143-2146

Authors: Tagat, JR Steensma, RW McCombie, SW Nazareno, DV Lin, SI Neustadt, BR Cox, K Xu, S Wojcik, L Murray, MG Vantuno, N Baroudy, BM Strizki, JM

Citation: Jr. Tagat et al., Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist, J MED CHEM, 44(21), 2001, pp. 3343-3346